10/4/2022
Phase 2 Clinical Trial for Celiac Disease
The PROACTIVE Celiac Study is a phase 2 clinical trial testing the safety and effects of the investigational medication PRV-015.
Continue ReadingFeatured News
Tag: PRV-015
10/7/2020
Celiac Disease Foundation Partners with Provention Bio on Its Phase 2b Study of Celiac Disease Therapeutic PRV-015
The Foundation is pleased to announce its partnership with Provention Bio to provide clinical trial recruitment for its Phase 2b PROACTIVE Celiac Study for PRV-015 (an anti-interleukin-15 monoclonal antibody).
Continue Reading8/31/2020
Stay Gluten-Free in New Celiac Clinical Trial
PROACTIVE Celiac Study is a phase 2 clinical trial testing the investigational medication PRV-015. In combination with a gluten-free diet, PRV-015 aims to reduce symptoms and intestinal inflammation caused by accidental gluten exposure.
Continue ReadingRecent Posts
- Exploring the Intersection of Nutrition Science and Policy: Highlights from the NIH-FDA Workshop
- Challenges Persist for Students with Celiac Disease in Free School Meal Programs
- Please Join Us for the Teal Pumpkin Project 2024!
- Why Aren't Most Rice Krispy Treats Gluten-Free?
Search the archive
Categories
- Advocacy News
- Celiac Disease in the News
- Clinical Trials
- Eat! Gluten-Free
- Featured
- Foundation Press
- iCureCeliac
- Marilyn’s Message
- Monthly eNewsletter
- Patient Profile Advocacy Series
- Research News
- Research Press
- Trending Topics
Marilyn's Message
9/26/2024
Read more2024 International Celiac Disease Symposium Recap
Last month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller co-chaired the End Points in Clinical Trials session with Dr. Francisco Leon, CEO...